World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
137
Citations
117444
World Ranking
1852
National Ranking
1054

Michael B. Atkins publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael B. Atkins sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 748 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael B. Atkins D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael B. Atkins sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 137 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael B. Atkins is affiliated with Georgetown University in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Economics and Econometrics.

The scientist's work concentrates on several key topics such as Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics, CAR-T cell therapy research, Renal and related cancers, Economic and Financial Impacts of Cancer, and Melanoma and MAPK Pathways.

Frequent publication venues for Michael B. Atkins include:

  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology
  • Clinical Cancer Research
  • Cancer Research

Their recent papers demonstrate active involvement in clinical oncology and cancer research, including:

  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020), The Lancet Oncology
  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma (2023), New England Journal of Medicine
  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade (2020), Cancer Cell
  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma (2020), Annals of Oncology
  • Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 (2022), Journal of Clinical Oncology

Michael B. Atkins collaborates frequently with several researchers, including:

  • David F. McDermott
  • Brian I. Rini
  • Toni K. Choueiri
  • Opeyemi A. Jegede
  • Elizabeth R. Plimack

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Comprehensivemolecular characterization of clear cell renal cell carcinoma

    Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

    Charles M. Balch;Antonio C. Buzaid;Seng-Jaw Soong;Michael B. Atkins

  • Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

    Charles M. Balch;Seng-Jaw Soong;Jeffrey E. Gershenwald;John F. Thompson

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

    Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

    Geoffrey T Gibney;Louis M Weiner;Michael B Atkins

  • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

    Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

    Herbert Tilg;Elizabeth Trehu;Michael B. Atkins;Charles A. Dinarello

  • Management of cutaneous melanoma.

    Hensin Tsao;Michael B Atkins;Arthur J Sober

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

Frequent Co-Authors

David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
James W. Mier
James W. Mier Beth Israel Deaconess Medical Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
F. Stephen Hodi
F. Stephen Hodi Harvard University
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Mario Sznol
Mario Sznol Yale University
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Those aspiring to advance their careers in medicine or healthcare have several online degree options beyond traditional medical school. Programs such as the cheapest mha online programs allow professionals to move into healthcare management roles and gain essential leadership skills while studying affordably.

For nurses aiming to reach the highest clinical expertise, pursuing the cheapest dnp (Doctor of Nursing Practice) programs online is a cost-effective way to earn an advanced practice degree and expand your career impact.

Pharmacists and those interested in pharmaceuticals can consider the best online pharmacy school options. These allow working professionals to earn an accredited PharmD degree with flexible schedules.

Additionally, for those drawn to the intersection of technology and healthcare, online schools for health information management offer pathways to careers managing medical data, security, and patient information.

Exploring these online programs can widen your career opportunities in healthcare while offering flexible study and affordable tuition options.

Best Scientists Citing Michael B. Atkins

Trending Scientists

Recently Published Articles